Imen Gharsallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Imen Gharsallah has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Maroua Slouma
Pain Center, Rabta Hospital, Tunis, Tunisia
8 shared publications - B. Louzir
Internal Medicine Department Tunisian Military Hospital, Tunis, TUNISIA
7 shared publications F. Ajili
7 shared publicationsS. Othmani
7 shared publicationsL. Metoui
6 shared publicationsN. Boussetta
6 shared publications
Latest Publications
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22 (2) , 1-7
Ultrasonographic Features of Amyloid Arthropathy in Light Chain Amyloidosis: A Case Report
Background: Amyloid arthropathy is characterized by the deposition of misfolded proteins in the joints and soft tissues. It is often a manifestation of light chain amyloidosis. The ultrasonographic features of amyloid arthropathy are solely reported in the literature. Case Presentation: Herein, we present the case of a 70-year-old patient who was diagnosed with light chain amyloidosis. He reported chronic joint pain, bilateral carpal tunnel syndrome, and an inguinal mass. Ultrasound examination revealed tenosynovitis of the flexor digitorum tendons, the extensor carpi ulnaris tendon, and the long head of the biceps tendon, along with synovitis in the wrists, elbows, and shoulders, as well as knee joint effusion. The synovial thickening with heterogeneous echogenic material suggested amyloid deposition. Conclusion: This case underscored key ultrasonographic features of amyloid arthropathy, including synovial thickening with heterogeneous echogenic deposits, tenosynovitis, and subacromialsubdeltoid bursa involvement. Unlike rheumatoid arthritis, amyloidosis lacked erosions and power Doppler signal, highlighting imaging distinctions. The hypoechoic inguinal amyloidoma with calcifications further aligned with amyloid deposition. Although amyloidosis shares certain clinical features with dialysis-related β2-microglobulin amyloidosis (e.g., carpal tunnel syndrome, shoulder deposits), AL amyloidosis may exhibit unique patterns, such as diffuse synovial infiltration without hyperemia. However, ultrasound’s non-specificity necessitates histopathological confirmation. While systemic amyloidosis requires pathological confirmation, ultrasonography provides a rapid, cost-effective tool for early diagnostic guidance.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22 (2) , 1-7
Ultrasonographic Features of Amyloid Arthropathy in Light Chain Amyloidosis: A Case Report
Background: Amyloid arthropathy is characterized by the deposition of misfolded proteins in the joints and soft tissues. It is often a manifestation of light chain amyloidosis. The ultrasonographic features of amyloid arthropathy are solely reported in the literature. Case Presentation: Herein, we present the case of a 70-year-old patient who was diagnosed with light chain amyloidosis. He reported chronic joint pain, bilateral carpal tunnel syndrome, and an inguinal mass. Ultrasound examination revealed tenosynovitis of the flexor digitorum tendons, the extensor carpi ulnaris tendon, and the long head of the biceps tendon, along with synovitis in the wrists, elbows, and shoulders, as well as knee joint effusion. The synovial thickening with heterogeneous echogenic material suggested amyloid deposition. Conclusion: This case underscored key ultrasonographic features of amyloid arthropathy, including synovial thickening with heterogeneous echogenic deposits, tenosynovitis, and subacromialsubdeltoid bursa involvement. Unlike rheumatoid arthritis, amyloidosis lacked erosions and power Doppler signal, highlighting imaging distinctions. The hypoechoic inguinal amyloidoma with calcifications further aligned with amyloid deposition. Although amyloidosis shares certain clinical features with dialysis-related β2-microglobulin amyloidosis (e.g., carpal tunnel syndrome, shoulder deposits), AL amyloidosis may exhibit unique patterns, such as diffuse synovial infiltration without hyperemia. However, ultrasound’s non-specificity necessitates histopathological confirmation. While systemic amyloidosis requires pathological confirmation, ultrasonography provides a rapid, cost-effective tool for early diagnostic guidance.
- Open Access
- 20 September 2025
- Published by The Korean Academy of Family Medicine - M2PI in Korean Journal of Family Medicine
- Vol. 46 (5) , 341-348
Aquatic versus land-based exercise for knee osteoarthritis: a randomized controlled trial
Background: Whether land- or aquatic-based rehabilitation is more effective in improving knee osteoarthritis (OA) is still unclear. This study assessed the effectiveness of aquatic-based treatments in patients with knee OA.Methods: The participants were divided into a land-based exercise group (G1, n=30) and a water-based exercise group (G2, n=30). The exercises were performed for 8 weeks. The primary endpoint was a response to physical therapy, defined as a 20% decrease in the summed score for the Western Ontario and McMaster Universities-Osteoarthritis Index (WOMAC) pain subscale from T1 (before the start of the rehabilitation program) to T2 (8 weeks later). The secondary endpoints included the Visual Analog Scale (VAS) for pain, WOMAC functional and stiffness subscales, Lequesne Index, and Medical Outcome Study Short Form (SF-12) for physical and mental health.Results: A 20% decrease in the summed WOMAC pain subscale score was noted in 33% of patients in G1 (n=10) and 93% in G2 (n=28) (P<0.001). VAS scores at walking decreased by 14% in G1 vs. 37% in G2 (P<0.001), WOMAC stiffness subscale decreased by 18% in G1 vs. 53% in G2 (P<0.001), and the Lequesne index decreased by 10% in G1 vs. 33% in G2 (P<0.001). Quality of life improvement was greater in G2 than in G1; SF-12 (physical) increased by 2.3 in G1 vs. 5.4 in G2 (P=0.023), and SF-12 (mental) increased by 6.3 in G1 vs. 10.9 in G2 (P=0.022).Conclusion: Both aquatic and land-based exercises improved pain intensity, functional impairment, degree of handicap, and quality of life impairment caused by OA. However, the improvement was more significant in the aquatic-based exercises group.
- 20 September 2025
- Published by The Korean Academy of Family Medicine - M2PI in Korean Journal of Family Medicine
- Vol. 46 (5) , 341-348
Open AccessAquatic versus land-based exercise for knee osteoarthritis: a randomized controlled trial
Background: Whether land- or aquatic-based rehabilitation is more effective in improving knee osteoarthritis (OA) is still unclear. This study assessed the effectiveness of aquatic-based treatments in patients with knee OA.Methods: The participants were divided into a land-based exercise group (G1, n=30) and a water-based exercise group (G2, n=30). The exercises were performed for 8 weeks. The primary endpoint was a response to physical therapy, defined as a 20% decrease in the summed score for the Western Ontario and McMaster Universities-Osteoarthritis Index (WOMAC) pain subscale from T1 (before the start of the rehabilitation program) to T2 (8 weeks later). The secondary endpoints included the Visual Analog Scale (VAS) for pain, WOMAC functional and stiffness subscales, Lequesne Index, and Medical Outcome Study Short Form (SF-12) for physical and mental health.Results: A 20% decrease in the summed WOMAC pain subscale score was noted in 33% of patients in G1 (n=10) and 93% in G2 (n=28) (P<0.001). VAS scores at walking decreased by 14% in G1 vs. 37% in G2 (P<0.001), WOMAC stiffness subscale decreased by 18% in G1 vs. 53% in G2 (P<0.001), and the Lequesne index decreased by 10% in G1 vs. 33% in G2 (P<0.001). Quality of life improvement was greater in G2 than in G1; SF-12 (physical) increased by 2.3 in G1 vs. 5.4 in G2 (P=0.023), and SF-12 (mental) increased by 6.3 in G1 vs. 10.9 in G2 (P=0.022).Conclusion: Both aquatic and land-based exercises improved pain intensity, functional impairment, degree of handicap, and quality of life impairment caused by OA. However, the improvement was more significant in the aquatic-based exercises group.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 20 (4) , 526-531
Parsonage-Turner Syndrome Following AstraZeneca COVID-19 Vaccination
Introduction: Parsonage-Turner Syndrome is an uncommon cause of shoulder pain Case Representation: Herein, we present the case of a male in his 40s, who was presented with a 3-month history of acute onset of intense shoulder pain, which decreased rapidly leaving behind a residual upper limb weakness. The diagnosis of Parsonage-Turner Syndrome following COVID-19 vaccination was made based on electroneuromyography and magnetic resonance imaging findings. The patient responded well to analgesics and rehabilitation. Conclusion: A better knowledge of this disease and early recognition are crucial to prevent unnecessary tests and interventions.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 20 (4) , 526-531
Parsonage-Turner Syndrome Following AstraZeneca COVID-19 Vaccination
Introduction: Parsonage-Turner Syndrome is an uncommon cause of shoulder pain Case Representation: Herein, we present the case of a male in his 40s, who was presented with a 3-month history of acute onset of intense shoulder pain, which decreased rapidly leaving behind a residual upper limb weakness. The diagnosis of Parsonage-Turner Syndrome following COVID-19 vaccination was made based on electroneuromyography and magnetic resonance imaging findings. The patient responded well to analgesics and rehabilitation. Conclusion: A better knowledge of this disease and early recognition are crucial to prevent unnecessary tests and interventions.
- Open Access
- 6 December 2024
- Published by Knowledge E DMCC in Journal of Spine Practice (JSP)
- Vol. 4 (1) , 35-42
Thoracic Radiculopathy Unveiling Giant Bilateral Thoracic Tarlov Cysts
Background Tarlov cysts, also known as perineural cysts, are fluid-filled sacs that typically arise between the covering layers of the perineurium and endoneurium at the junction of the dorsal root ganglion. They are usually asymptomatic and typically located at the lumbosacral spine. Thoracic localization is rarely reported and is a challenging condition both clinically due to its misleading wide range of symptoms and therapeutically, given the lack of management guidelines. Case We report a case of a man in his seventies complaining of chronic back pain with worsening bilateral thoracic radiculopathy with tingling and burning sensations following T11-T12 dermatomes. The neurological examination was without abnormalities. Magnetic resonance imaging revealed bilateral, extradural, and large cystic formations. The diagnosis of thoracic bilateral giant cysts was established. The patient denied surgical treatment. Topical non-steroidal anti-inflammatory drugs and acetaminophen led to partial improvement of symptoms. Conclusion This case highlights clinical and imaging features of thoracic Tarlov cysts. The MRI is considered the gold standard for diagnosing Tarlov cysts and effectively ruling out differential diagnoses. The initial therapeutic approach for Tarlov cysts typically involves conservative management.
- 6 December 2024
- Published by Knowledge E DMCC in Journal of Spine Practice (JSP)
- Vol. 4 (1) , 35-42
Open AccessThoracic Radiculopathy Unveiling Giant Bilateral Thoracic Tarlov Cysts
Background Tarlov cysts, also known as perineural cysts, are fluid-filled sacs that typically arise between the covering layers of the perineurium and endoneurium at the junction of the dorsal root ganglion. They are usually asymptomatic and typically located at the lumbosacral spine. Thoracic localization is rarely reported and is a challenging condition both clinically due to its misleading wide range of symptoms and therapeutically, given the lack of management guidelines. Case We report a case of a man in his seventies complaining of chronic back pain with worsening bilateral thoracic radiculopathy with tingling and burning sensations following T11-T12 dermatomes. The neurological examination was without abnormalities. Magnetic resonance imaging revealed bilateral, extradural, and large cystic formations. The diagnosis of thoracic bilateral giant cysts was established. The patient denied surgical treatment. Topical non-steroidal anti-inflammatory drugs and acetaminophen led to partial improvement of symptoms. Conclusion This case highlights clinical and imaging features of thoracic Tarlov cysts. The MRI is considered the gold standard for diagnosing Tarlov cysts and effectively ruling out differential diagnoses. The initial therapeutic approach for Tarlov cysts typically involves conservative management.
- 30 December 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (3) , 929-938
Associated factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate
Introduction There are conflicting findings on the link between liver fibrosis and cumulative methotrexate dosages. We aimed to determine the frequency of liver fibrosis in rheumatoid arthritis patients treated with methotrexate and to identify its associated factors. Methods We conducted a cross-sectional study over 9 months (April–December 2021), including rheumatoid arthritis patients treated with methotrexate. Demographic and clinical data were collected. Liver stiffness was assessed by FibroScan. Fibrosis and significant liver fibrosis were defined as liver stiffness higher than 6 and 7.2 kPa, respectively. Liver tests, albuminemia, lipid profile, and blood glycemia were measured. Metabolic syndrome was also evaluated. Statistical analyses were performed using SPSS. Results We included 21 men and 47 women. The mean age was 51.60 ± 1.82 years. The mean disease duration was 8.29 ± 6.48 years. The mean weekly intake of methotrexate was 13.76 ± 3.91 mg. The mean methotrexate duration was 4.67 ± 4.24 years. The mean cumulative dose was 3508.87 ± 3390.48 mg. Hypoalbuminemia and metabolic syndrome were found in 34% and 25% of cases. We noted increased alkaline phosphatase levels in four cases. The mean liver stiffness was 4.50 ± 1.53 kPa. Nine patients had liver fibrosis, and four had significant fibrosis. Associated factors with liver fibrosis were as follows: age ≥ 60 years (OR:22.703; 95%CI [1.238–416.487]; p = 0.035), cumulated dose of methotrexate ≥ 3 g (OR: 76.501; 95%CI [2.383–2456.070]; p = 0.014), metabolic syndrome (OR: 42.743; 95%CI [1.728–1057.273]; p = 0.022), elevated alkaline phosphatase levels (OR: 28.252; 95%CI [1.306–611.007]; p = 0.033), and hypoalbuminemia (OR: 59.302; 95%CI [2.361–1489.718]; p = 0.013). Conclusion Cumulating more than 3 g of methotrexate was associated with liver fibrosis in rheumatoid arthritis patients. Having a metabolic syndrome, higher age, hypoalbuminemia, and elevated alkaline phosphatase levels were also likely to be independently associated with liver fibrosis. Key points • Rheumatoid arthritis patients require monitoring hepatic fibrosis when the cumulated dose of methotrexate is above 3 g. • Metabolic syndrome is a risk factor for liver fibrosis, suggesting that its management is necessary to prevent this complication. • Hypoalbuminemia and elevated alkaline phosphatase levels (twice the upper limit) in rheumatoid arthritis patients treated with methotrexate were associated with liver fibrosis.
- 30 December 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (3) , 929-938
Associated factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate
Introduction There are conflicting findings on the link between liver fibrosis and cumulative methotrexate dosages. We aimed to determine the frequency of liver fibrosis in rheumatoid arthritis patients treated with methotrexate and to identify its associated factors. Methods We conducted a cross-sectional study over 9 months (April–December 2021), including rheumatoid arthritis patients treated with methotrexate. Demographic and clinical data were collected. Liver stiffness was assessed by FibroScan. Fibrosis and significant liver fibrosis were defined as liver stiffness higher than 6 and 7.2 kPa, respectively. Liver tests, albuminemia, lipid profile, and blood glycemia were measured. Metabolic syndrome was also evaluated. Statistical analyses were performed using SPSS. Results We included 21 men and 47 women. The mean age was 51.60 ± 1.82 years. The mean disease duration was 8.29 ± 6.48 years. The mean weekly intake of methotrexate was 13.76 ± 3.91 mg. The mean methotrexate duration was 4.67 ± 4.24 years. The mean cumulative dose was 3508.87 ± 3390.48 mg. Hypoalbuminemia and metabolic syndrome were found in 34% and 25% of cases. We noted increased alkaline phosphatase levels in four cases. The mean liver stiffness was 4.50 ± 1.53 kPa. Nine patients had liver fibrosis, and four had significant fibrosis. Associated factors with liver fibrosis were as follows: age ≥ 60 years (OR:22.703; 95%CI [1.238–416.487]; p = 0.035), cumulated dose of methotrexate ≥ 3 g (OR: 76.501; 95%CI [2.383–2456.070]; p = 0.014), metabolic syndrome (OR: 42.743; 95%CI [1.728–1057.273]; p = 0.022), elevated alkaline phosphatase levels (OR: 28.252; 95%CI [1.306–611.007]; p = 0.033), and hypoalbuminemia (OR: 59.302; 95%CI [2.361–1489.718]; p = 0.013). Conclusion Cumulating more than 3 g of methotrexate was associated with liver fibrosis in rheumatoid arthritis patients. Having a metabolic syndrome, higher age, hypoalbuminemia, and elevated alkaline phosphatase levels were also likely to be independently associated with liver fibrosis. Key points • Rheumatoid arthritis patients require monitoring hepatic fibrosis when the cumulated dose of methotrexate is above 3 g. • Metabolic syndrome is a risk factor for liver fibrosis, suggesting that its management is necessary to prevent this complication. • Hypoalbuminemia and elevated alkaline phosphatase levels (twice the upper limit) in rheumatoid arthritis patients treated with methotrexate were associated with liver fibrosis.
- Open Access
- 5 January 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (4) , 1217-1218
Febrile neck pain: a tale of the crowned dens
- 5 January 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (4) , 1217-1218
Open AccessFebrile neck pain: a tale of the crowned dens
- 1 December 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (2) , 607-620
Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature review
- 1 December 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (2) , 607-620
Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature review
- 5 July 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (8) , 2609-2610
Post-COVID-19 reactive arthritis
- 5 July 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (8) , 2609-2610
Post-COVID-19 reactive arthritis
- 21 January 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (5) , e168-e169
Skeletal Manifestations of Autoimmune Hypoparathyroidism
An abstract is unavailable. This article is available as a PDF only.
- 21 January 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (5) , e168-e169
Skeletal Manifestations of Autoimmune Hypoparathyroidism
An abstract is unavailable. This article is available as a PDF only.
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 393-394
Paralysie périodique hypokaliémique thyréotoxique (PPHT) : à propos d’un cas
- 1 September 2016
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 77 (4) , 393-394
Paralysie périodique hypokaliémique thyréotoxique (PPHT) : à propos d’un cas